Cassie Corneau
Senior Director, Investor Relations and Strategic Finance
Replay available
10x Genomics, Inc. (NASDAQ: TXG) Q1 2026 earnings conference call, held 2026-05-07. Replay captured from the company's public earnings webcast.

Senior Director, Investor Relations and Strategic Finance
CEO & Co-founder
Chief Financial Officer
Analyst, Citi
Analyst, William Blair
Analyst, Wolf Research
Analyst, Stevens
Analyst, Barclays
Analyst, Canaccord
Analyst, Deutsche Bank
Analyst, WeRank Partners
Good afternoon and welcome to 10X Genomics first quarter 2026 earnings conference call. All participants are in a listen-only mode. After the speaker's remarks, we will conduct a question and answer session. To ask a question at this time, you'll need to press star followed by the number one on your telephone keypad. As a reminder, this conference call is being recorded. I would now like to turn the call over to Cassie Corneau, Senior Director, Investor Relations and Strategic Finance. Thank you. Please go ahead. Thank you, and good afternoon, everyone. Earlier today, 10x Genomics released financial results for the first quarter ended March 31st, 2026. If you have not received this news release or would like to be added to the company's distribution list, please send an email to investors at 10xgenomics.com. An archived webcast of this call will be available on the investor tab of the company's website, 10xgenomics.com, for at least 45 days following this call. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated, and you should not place undue reliance on forward-looking statements. Additional information regarding these risks, uncertainties, and factors that could cause results to differ appears in the press release 10X Genomics issued today. and in the documents and reports filed by 10X Genomics from time to time with the Securities and Exchange Commission. 10X Genomics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of...